SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001640334-23-000736
Filing Date
2023-05-02
Accepted
2023-05-02 08:29:48
Documents
107
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 20-F nymox_20f.htm   iXBRL 20-F 1498027
2 EX-12.A nymox_ex12a.htm EX-12.A 9751
3 EX-12.B nymox_ex12b.htm EX-12.B 9034
4 EX-13.A nymox_ex13a.htm EX-13.A 2868
5 EX-13.B nymox_ex13b.htm EX-13.B 2843
  Complete submission text file 0001640334-23-000736.txt   5793770

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA nymox-20221231.xsd EX-101.SCH 91029
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymox-20221231_lab.xml EX-101.LAB 288445
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymox-20221231_cal.xml EX-101.CAL 52717
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymox-20221231_pre.xml EX-101.PRE 253587
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymox-20221231_def.xml EX-101.DEF 136350
101 EXTRACTED XBRL INSTANCE DOCUMENT nymox_20f_htm.xml XML 1014651
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 23876724
SIC: 2835 In Vitro & In Vivo Diagnostic Substances